A randomized, placebo-controlled trial of melatonin on breast cancer survivors: Impact on sleep, mood, and hot flashes

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 381-388

  Chen, Wendy Y ^a,b   Giobbie Hurder, Anita ^b   Gantman, Kathryn ^c   Savoie, Jennifer ^b   Scheib, Rochelle ^b   Parker, Leroy M ^b   Schernhammer, Eva S ^a,d,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MOUNT AUBURN HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ACR ITR   (Austria)

Author keywords

Breast cancer; Clinical trial; Melatonin; Sleep disturbance; Survivorship

Indexed keywords

MELATONIN; PLACEBO;

ADULT; AGED; ARTICLE; CANCER SURVIVOR; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PITTSBURGH SLEEP QUALITY INDEX; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP QUALITY; TREATMENT OUTCOME; UNPLEASANT DREAM; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; AFFECT; BREAST TUMOR; DRUG EFFECTS; HOT FLASHES; MIDDLE AGED; QUALITY OF LIFE; SLEEP INITIATION AND MAINTENANCE DISORDERS; SURVIVOR;

ADULT; AFFECT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; MELATONIN; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; SLEEP INITIATION AND MAINTENANCE DISORDERS; SURVIVORS; TREATMENT OUTCOME;

EID: 84901689379     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2944-4     Document Type: Article

References (35)

1. Fiorentino L, Ancoli-Israel S (2006) Insomnia and its treatment in women with breast cancer. Sleep Med Rev 10(6):419-429 (Pubitemid 44810065)
2. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332(7538):385-393 (Pubitemid 43797377)
3. Herxheimer A, Petrie KJ (2002) Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews
4. Cardinali DP, Srinivasan V, Brzezinski A, Brown GM (2012) Melatonin and its analogs in insomnia and depression. J Pineal Res 52(4):365-375
5. Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E (2001) Effects of melatonin in perimenopausal and menopausal women: A randomized and placebo controlled study. Exp Gerontol 36(2):297-310 (Pubitemid 32162483)
6. Iguichi H, Kato KI, Ibayashi H (1982) Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 55(1):27-29 (Pubitemid 13250320)
7. Jung B, Ahmad N (2006) Melatonin in cancer management: progress and promise. Cancer Res 66(20):9789-9793 (Pubitemid 44672026)
8. Mills E, Wu P, Seely D, Guyatt G (2005) Melatonin in the treatment of cancer: A systematic review of randomized controlled trials and meta-analysis. J Pineal Res 39(4):360-366
9. Schernhammer ES, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Chen WY (2012) A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers. Cancer Causes Control 23(4):609-616
10. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatr Res 28(2):193-213 (Pubitemid 19144991)
11. Hann D, Winter K, Jacobsen P (1999) Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 46(5):437-443 (Pubitemid 29277215)
12. Radloff LS (1977) The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Measure 1:385-401
13. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19(23):4280-4290 (Pubitemid 33096775)
14. Courneya KS, Sellar CM, Trinh L, Forbes CC, Stevinson C, McNeely ML, Peddle-McIntyre CJ, Friedenreich CM, Reiman T (2012) A randomized trial of aerobic exercise and sleep quality in lymphoma patients receiving chemotherapy or no treatments. Cancer Epidemiol Biomarkers Prev 21(6):887-894
15. Payne JK, Held J, Thorpe J, Shaw H (2008) Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. Oncol Nurs Forum 35(4):635-642
16. Yurcheshen ME, Guttuso T Jr, McDermott M, Holloway RG, Perlis M (2009) Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Womens Health (Larchmt) 18(9):1355-1360
17. van Geijlswijk IM, Korzilius HP, Smits MG (2010) The use of exogenous melatonin in delayed sleep phase disorder: A meta-analysis. Sleep 33(12):1605-1614
18. Alfano CM, Lichstein KL, Vander Wal GS, Smith AW, Reeve BB, Mc Tiernan A, Bernstein L, Baumgartner KB, Ballard-Barbash R (2011) Sleep duration change across breast cancer survivorship: Associations with symptoms and health-related quality of life. Breast Cancer Res Treat 130(1):243-254
19. Otte JL, Carpenter JS, Russell KM, Bigatti S, Champion VL (2010) Prevalence, severity, and correlates of sleep-wake disturbances in long-term breast cancer survivors. J Pain Symptom Manage 39(3):535-547
20. Berger AM, Kuhn BR, Farr LA, Von Essen SG, Chamberlain J, Lynch JC, Agrawal S (2009) One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol 27(35):6033-6040
21. Epstein DR, Dirksen SR (2007) Randomized trial of a cognitive-behavioral intervention for insomnia in breast cancer survivors. Oncol Nurs Forum 34(5):E51-E59
22. Savard J, Simard S, Ivers H, Morin CM (2005) Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part II: immunologic effects. J Clin Oncol 23(25):6097-6106
23. Secreto G, Chiechi LM, Amadori A, Miceli R, Venturelli E, Valerio T, Marubini E (2004) Soy isoflavones and melatonin for the relief of climacteric symptoms: A multicenter, double-blind, randomized study. Maturitas 47(1):11-20 (Pubitemid 38050011)
24. Kotlarczyk MP, Lassila HC, O'Neil CK, D'Amico F, Enderby LT, Witt-Enderby PA, Balk JL (2012) Melatonin osteoporosis prevention study (MOPS): A randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res 52(4):414-426
25. Hickie IB, Rogers NL (2011) Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378(9791):621-631
26. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G (1999) Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35(12):1688-1692 (Pubitemid 30050641)
27. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G (1995) Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71(4):854-856
28. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G (2003) Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res 35(1):12-15 (Pubitemid 36819165)
29. Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A, Maestroni GJ (1997) A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 23(1):15-19 (Pubitemid 127500264)
30. Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T, Asch HL (2002) Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol 118(3):451-458 (Pubitemid 37046344)
31. Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ (1998) Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58:4383-4390 (Pubitemid 28450041)
32. Cos S, Sanchez-Barcelo EJ (2000) Melatonin and mammary pathological growth. Front Neuroendocrinol 21(2):133-170 (Pubitemid 30228502)
33. Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA (2009) Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 11:e5
34. Sanchez-Barcelo EJ, Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A, Alonso-Gonzalez C (2005) Melatonin-estrogen interactions in breast cancer. J Pineal Res 38(4):217-222 (Pubitemid 41475432)
35. Jablonska K, Pula B, Zemla A, Owczarek T, Wojnar A, Rys J, Ambicka A, Podhorska-Okolow M, Ugorski M, Dziegiel P (2013) Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. J Pineal Res 54(3):334-345